Increased serum HMGB1 level may predict the fatal outcomes in patients with chronic heart failure

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 318-320

  Liu, Tao ^a   Zhang, De Yong ^a   Zhou, Yan Hong ^a   Han, Qian Feng ^a   Wang, Lan Hua ^a   Wu, Lei ^a   Yao, Heng Chen ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Heart failure; High mobility group box 1; Mortality; N terminal pro brain natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH MOBILITY GROUP B1 PROTEIN; BIOLOGICAL MARKER; HMGB1 PROTEIN, HUMAN;

ADULT; AGED; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; ISCHEMIC CARDIOMYOPATHY; LETTER; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CHRONIC DISEASE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 84929174980     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.02.088     Document Type: Article

References (16)

1. J. Li, R. Kokkola, S. Tabibzadeh, R. Yang, M. Ochani, X. Qiang, H. E. Harris, C. J. Czura, H. Wang, L. Ulloa, H. Wang, H. S. Warren, L. L. Moldawer, M. P. Fink, U. Andersson, K. J. Tracey, H. Yang, Structural basis for the proinflammatory cytokine activity of high mobility group box 1, Mol. Med. 9 (2003) 37-45.
2. J. O. Thomas, HMG1 and 2: architectural DNA-binding proteins, Biochem. Soc. Trans. 29 (2001) 395-401.
3. I. E. Dumitriu, P. Baruah, A. A. Manfredi, M. E. Bianchi, P. Rovere-Querini, HMGB1: guiding immunity from within, Trends Immunol. 26 (2005) 381-387.
4. T. Kohno, T. Anzai, K. Naito, T. Miyasho, M. Okamoto, H. Yokota, S. Yamada, Y. Maekawa, T. Takahashi, T. Yoshikawa, A. Ishizaka, S. Ogawa, Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling, Cardiovasc. Res. 81 (2009) 565-573.
5. K. Inoue, K. Kawahara, K. K. Biswas, K. Ando, K. Mitsudo, M. Nobuyoshi, I. Maruyama, HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques, Cardiovasc. Pathol. 16 (2007) 136-143.
6. H. S. Ding, J. Yang, Highmobility group box-1 and cardiovascular diseases, Saudi Med J. 31 (2010) 486-489.
7. A. M. Avalos, K. Kiefer, J. Tian, S. Christensen, M. Shlomchik, A. J. Coyle, A. Marshak-Rothstein, Rage-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes, Autoimmunity 43 (2010) 103-110.
8. H. C. Yao, A. P. Zhao, Q. F. Han, L. Wu, D. K. Yao, L. X. Wang, Correlation between serum high-mobility group box-1 levels and high-sensitivity C-reactive protein and troponin I in patients with coronary artery disease, Exp. Ther. Med. 6 (2013) 121-124.
9. H. C. Yao, L. J. Yang, Q. F. Han, L. H. Wang, L. Wu, C. Y. Zhang, K. L. Tian, M. Zhang, Postconditioning with simvastatin decreases themyocardial injury in rats following acute myocardial ischemia, Exp. Ther. Med. (2015) (accepted, in press).
10. M. Rauchhaus, W. Doehner, D. P. Francis, C. Davos, M. Kemp, C. Liebenthal, J. Niebauer, J. Hooper, H. D. Volk, A. J. Coats, S. D. Anker, Plasma cytokine parameters and mortality in patients with chronic heart failure, Circulation 102 (2000) 3060-3067.
11. A. Deswal, N. J. Petersen, A. M. Feldman, J. B. Young, B. G. White, D. L. Mann, Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (vest), Circulation 103 (2001) 2055-2059.
12. L. J. Wang, L. Lu, F. R. Zhang, Q. J. Chen, R. De Caterina, W. F. Shen, Increased serumhighmobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure, Eur. J. Heart Fail. 13 (2011) 440-449.
13. H. C. Volz, D. Laohachewin, D. Schellberg, A. R. Wienbrandt, M. Nelles, C. Zugck, Z. Kaya, H. A. Katus, M. Andrassy, HMGB1 is an independent predictor of death and heart transplantation in heart failure, Clin. Res. Cardiol. 101 (2012) 427-435.
14. M. Andrassy, H. C. Volz, J. C. Igwe, B. Funke, S. N. Eichberger, Z. Kaya, S. Buss, F. Autschbach, S. T. Pleger, I. K. Lukic, F. Bea, S. E. Hardt, P. M. Humpert, M. E. Bianchi, H. Mairbäurl, P. P. Nawroth, A. Remppis, H. A. Katus, A. Bierhaus, High-mobility group box-1 in ischemia-reperfusion injury of the heart, Circulation 117 (2008) 3216-3226.
15. Z. Su, C. Sun, C. Zhou, Y. Liu, H. Zhu, S. Sandoghchian, D. Zheng, T. Peng, Y. Zhang, Z. Jiao, S. Wang, H. Xu, HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses TH17-cell expansion, Eur. J. Immunol. 41 (2011) 3586-3595.
16. M. R. Cowie, A. D. Struthers, D. A. Wood, A. J. Coats, S. G. Thompson, P. A. Poole-Wilson, G. C. Sutton, Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care, Lancet 350 (1997) 1349-1353.